EICHORCondition: Biliary Tract or Colorectal Cancer With Her2-positive/Mutated · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
This description comes directly from the study's public registry record.
Jianming Xu · 0086-010-66937166 · jfjzyygw@163.com
Always discuss trial participation with your own doctor first.
| Beijing Friendship Hospital，Capital Medical University | Beijing, China | Recruiting |
| Chinese PLA General hospital | Beijing, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, China | Recruiting |
| The Second Affiliatedf Hospital of AFMU | Beijing, China | Recruiting |
| XiangYa Hospital CentralSouth University | Changsha, China | Recruiting |
| Changzhi People's Hospital | Changzhi, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| General Hospital of Fuzhou | Fuzhou, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Recruiting |
| Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Zhejiang Cancer Hospital | Hangzhou, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, China | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06434597